Fluoxetine is used for the treatment of major depressive disorder, obsessive-compulsive disorder, bulimia nervosa and panic disorder, with or without agoraphobia.
As of April 2024, the FDA has approved a total of 48 biosimilars across 15 unique biological molecules, and of the 48 approvals, 38 biosimilars have launched in the U.S. market, per the report.
